BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21832958)

  • 1. Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial.
    Schmeding M; Kiessling A; Neuhaus R; Heidenhain C; Bahra M; Neuhaus P; Neumann UP
    Transplantation; 2011 Oct; 92(8):923-9. PubMed ID: 21832958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
    Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
    Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
    Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
    Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mycophenolate mofetil in liver transplantation--is monotherapy safe?
    Schmeding M; Neumann UP; Neuhaus R; Neuhaus P
    Clin Transplant; 2006; 20 Suppl 17():75-9. PubMed ID: 17100705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of calcineurin inhibitor conversion to mycophenolate mofetil on renal function after liver transplantation.
    Créput C; Blandin F; Deroure B; Roche B; Saliba F; Charpentier B; Samuel D; Durrbach A
    Liver Transpl; 2007 Jul; 13(7):1004-10. PubMed ID: 17600361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
    Flechner SM; Kobashigawa J; Klintmalm G
    Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
    Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
    Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
    Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
    Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection.
    Krischock L; Gullett A; Bockenhauer D; Rees L; Trompeter RS; Marks SD
    Pediatr Transplant; 2009 Jun; 13(4):475-81. PubMed ID: 18992054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation.
    Jiménez-Pérez M; Lozano Rey JM; Marín García D; Olmedo Martín R; de la Cruz Lombardo J; Rodrigo López JM
    Transplant Proc; 2006 Oct; 38(8):2480-1. PubMed ID: 17097974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of mycophenolate mofetil monotherapy in patients after liver transplantation.
    Kamphues C; Bova R; Röcken C; Neuhaus R; Pratschke J; Neuhaus P; Neumann UP
    Ann Transplant; 2009; 14(4):40-6. PubMed ID: 20009154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients.
    Groetzner J; Kaczmarek I; Landwehr P; Mueller M; Daebritz S; Lamm P; Meiser B; Reichart B
    Eur J Cardiothorac Surg; 2004 Mar; 25(3):333-41. PubMed ID: 15019657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study.
    Beckebaum S; Klein CG; Sotiropoulos GC; Saner FH; Gerken G; Paul A; Cicinnati VR
    Transplant Proc; 2009; 41(6):2567-9. PubMed ID: 19715976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil monotherapy in liver transplant recipients.
    Kriss M; Sotil EU; Abecassis M; Welti M; Levitsky J
    Clin Transplant; 2011; 25(6):E639-46. PubMed ID: 22007615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 15-year follow-up of a multicenter, randomized, calcineurin inhibitor withdrawal study in kidney transplantation.
    Roodnat JI; Hilbrands LB; Hené RJ; de Sévaux RG; Smak Gregoor PJ; Kal-van Gestel JA; Konijn C; van Zuilen A; van Gelder T; Hoitsma AJ; Weimar W
    Transplantation; 2014 Jul; 98(1):47-53. PubMed ID: 24521775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.